Latigo Biotherapeutics Inc., a California-based clinical-stage biotechnology company, announced on Monday that it has named Nima Farzan, MBA as its new chief executive officer (CEO).

Farzan succeeds Desmond Padhi, Pharm D, operating partner at Westlake Village BioPartners, who has been serving as the company's interim CEO.

Farzan has over two decades of leadership experience in the biopharmaceutical industry. He has served as chief executive officer (CEO) of Kinnate Biopharma. He has served for seven years at PaxVax, where he most recently served as president and CEO. He has worked at Novartis AG in roles of increasing responsibility, including vice president of US Marketing at Novartis' Vaccines and Diagnostics division. He has earlier worked at DoubleTwist and was a consultant with Boston Consulting Group. He has worked as an executive-in-residence at Foresite Capital. He has served as a director of Keros Therapeutics and was a member of the founding board of the Coalition for Epidemic Preparedness Innovations (CEPI).